Abstract P4-01-17: Molecular imaging and quantification of HER-2 status in metastatic breast cancer by using 68Ga-ABY-025/PET-CT
Henrik Lindman(Uppsala University), Jens Christian Hedemann Sørensen(Uppsala University), Mattias Sandström(Uppsala University Hospital), Joachim Feldwisch(Uppsala University), Anders Wennborg(Affibody (Sweden)), Mark Lubberink(Uppsala University), Dan Sandberg(Uppsala University), Irina Velikyan(Uppsala University), Vladimir Tolmachev(Uppsala University), J. Carlsson(Landstinget i Kalmar län)
Cited by 2
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260
In Vivo Visualization of Amyloid Deposits in the Heart with <sup>11</sup>C-PIB and PET
|Journal of Nuclear Medicine|2012|258